Item 1.
|
Financial Statements.
|
Stellar Biotechnologies, Inc.
Condensed Interim Consolidated Balance Sheets
(Unaudited)
|
|
March 31,
|
|
|
September 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
7,684,120
|
|
|
$
|
4,225,521
|
|
Accounts receivable
|
|
|
40,046
|
|
|
|
41,246
|
|
Short-term investments
|
|
|
-
|
|
|
|
6,078,031
|
|
Inventory
|
|
|
243,972
|
|
|
|
224,267
|
|
Prepaid and other assets
|
|
|
170,792
|
|
|
|
86,919
|
|
Total current assets
|
|
|
8,138,930
|
|
|
|
10,655,984
|
|
|
|
|
|
|
|
|
|
|
Noncurrent assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity investment in joint venture
|
|
|
-
|
|
|
|
46,456
|
|
Property, plant and equipment, net
|
|
|
996,745
|
|
|
|
1,062,195
|
|
Deposits
|
|
|
15,340
|
|
|
|
15,340
|
|
Total noncurrent assets
|
|
|
1,012,085
|
|
|
|
1,123,991
|
|
Total Assets
|
|
$
|
9,151,015
|
|
|
$
|
11,779,975
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareholders' Equity:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
$
|
801,407
|
|
|
$
|
493,385
|
|
Deferred revenue
|
|
|
80,000
|
|
|
|
-
|
|
Total Current Liabilities
|
|
|
881,407
|
|
|
|
493,385
|
|
|
|
|
|
|
|
|
|
|
Commitments
(Note 7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders' equity:
|
|
|
|
|
|
|
|
|
Common shares, unlimited common shares authorized, no par value, 5,330,715 issued and outstanding at March 31, 2019 and September 30, 2018
|
|
|
56,652,957
|
|
|
|
56,652,957
|
|
Accumulated share-based compensation
|
|
|
5,109,824
|
|
|
|
5,064,625
|
|
Accumulated deficit
|
|
|
(53,493,173
|
)
|
|
|
(50,430,992
|
)
|
Total Shareholders' Equity
|
|
|
8,269,608
|
|
|
|
11,286,590
|
|
Total Liabilities and Shareholders' Equity
|
|
$
|
9,151,015
|
|
|
$
|
11,779,975
|
|
The accompanying notes are an integral part
of these condensed interim consolidated financial statements.
Stellar Biotechnologies, Inc.
Condensed Interim Consolidated Statements of Operations
(Unaudited)
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product sales
|
|
$
|
117,755
|
|
|
$
|
64,052
|
|
|
$
|
170,788
|
|
|
$
|
84,539
|
|
|
|
|
117,755
|
|
|
|
64,052
|
|
|
|
170,788
|
|
|
|
84,539
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
64,378
|
|
|
|
65,623
|
|
|
|
92,371
|
|
|
|
68,424
|
|
Costs of aquaculture
|
|
|
35,408
|
|
|
|
74,424
|
|
|
|
113,688
|
|
|
|
172,474
|
|
Research and development
|
|
|
375,734
|
|
|
|
493,873
|
|
|
|
846,017
|
|
|
|
1,124,907
|
|
General and administrative
|
|
|
1,325,693
|
|
|
|
773,989
|
|
|
|
2,208,491
|
|
|
|
1,452,470
|
|
|
|
|
1,801,213
|
|
|
|
1,407,909
|
|
|
|
3,260,567
|
|
|
|
2,818,275
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss from Operations
|
|
|
(1,683,458
|
)
|
|
|
(1,343,857
|
)
|
|
|
(3,089,779
|
)
|
|
|
(2,733,736
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Loss)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange gain (loss)
|
|
|
7,645
|
|
|
|
(16,218
|
)
|
|
|
(19,494
|
)
|
|
|
(34,147
|
)
|
Investment income
|
|
|
19,336
|
|
|
|
7,548
|
|
|
|
47,892
|
|
|
|
15,410
|
|
|
|
|
26,981
|
|
|
|
(8,670
|
)
|
|
|
28,398
|
|
|
|
(18,737
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss Before Income Tax
|
|
|
(1,656,477
|
)
|
|
|
(1,352,527
|
)
|
|
|
(3,061,381
|
)
|
|
|
(2,752,473
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
-
|
|
|
|
-
|
|
|
|
800
|
|
|
|
800
|
|
Net Loss
|
|
$
|
(1,656,477
|
)
|
|
$
|
(1,352,527
|
)
|
|
$
|
(3,062,181
|
)
|
|
$
|
(2,753,273
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
$
|
(0.31
|
)
|
|
$
|
(0.90
|
)
|
|
$
|
(0.57
|
)
|
|
$
|
(1.83
|
)
|
Weighted average number of common shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted
|
|
|
5,330,715
|
|
|
|
1,502,870
|
|
|
|
5,330,715
|
|
|
|
1,502,870
|
|
The accompanying notes are an integral part
of these condensed interim consolidated financial statements.
Stellar Biotechnologies, Inc.
Condensed Interim Consolidated Statements of Cash Flows
(Unaudited)
|
|
Six Months Ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Cash Flows Used In Operating Activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(3,062,181
|
)
|
|
$
|
(2,753,273
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
80,159
|
|
|
|
95,894
|
|
Share-based compensation
|
|
|
45,199
|
|
|
|
94,168
|
|
Foreign exchange (gain) loss
|
|
|
19,494
|
|
|
|
34,147
|
|
Loss on sale of subsidiary
|
|
|
18,928
|
|
|
|
-
|
|
Transfer equipment to research and development
|
|
|
32,018
|
|
|
|
12,419
|
|
Change in equity investment in joint venture
|
|
|
46,456
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Changes in working capital items:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
1,175
|
|
|
|
(61,549
|
)
|
Inventory
|
|
|
(19,705
|
)
|
|
|
(137,250
|
)
|
Prepaid and other assets
|
|
|
(83,914
|
)
|
|
|
(86,269
|
)
|
Accounts payable and accrued liabilities
|
|
|
308,122
|
|
|
|
268,845
|
|
Deferred revenue
|
|
|
80,000
|
|
|
|
-
|
|
Net cash used in operating activities
|
|
|
(2,534,249
|
)
|
|
|
(2,532,868
|
)
|
|
|
|
|
|
|
|
|
|
Cash Flows From Investing Activities:
|
|
|
|
|
|
|
|
|
Purchase of property, plant and equipment
|
|
|
(67,035
|
)
|
|
|
(205,891
|
)
|
Proceeds on sale of subsidiary
|
|
|
1,000
|
|
|
|
-
|
|
Purchase of short-term investments
|
|
|
(21,969
|
)
|
|
|
(505,222
|
)
|
Proceeds on sales and maturities of short-term investments
|
|
|
6,100,000
|
|
|
|
2,000,000
|
|
Net cash provided by investing activities
|
|
|
6,011,996
|
|
|
|
1,288,887
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
(19,148
|
)
|
|
|
(33,960
|
)
|
Net change in cash and cash equivalents
|
|
|
3,458,599
|
|
|
|
(1,277,941
|
)
|
Cash and cash equivalents - beginning of period
|
|
|
4,225,521
|
|
|
|
4,570,951
|
|
Cash and cash equivalents - end of period
|
|
$
|
7,684,120
|
|
|
$
|
3,293,010
|
|
|
|
|
|
|
|
|
|
|
Cash (demand deposits)
|
|
$
|
2,347,734
|
|
|
$
|
2,788,805
|
|
Cash equivalents
|
|
|
5,336,386
|
|
|
|
504,205
|
|
Cash and cash equivalents
|
|
$
|
7,684,120
|
|
|
$
|
3,293,010
|
|
|
|
|
|
|
|
|
|
|
Supplemental cash flow information:
|
|
|
|
|
|
|
|
|
Cash paid during the period for taxes
|
|
$
|
800
|
|
|
$
|
800
|
|
The accompanying notes are an integral part
of these condensed interim consolidated financial statements.
Stellar Biotechnologies, Inc.
Condensed Interim Consolidated Statements of Changes in Equity
(Unaudited)
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
Common
|
|
|
Share-Based
|
|
|
Accumulated
|
|
|
Shareholders'
|
|
|
|
Shares
|
|
|
Shares
|
|
|
Compensation
|
|
|
Deficit
|
|
|
Equity
|
|
Three Months Ended March 31, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - December 31, 2018
|
|
|
5,330,715
|
|
|
$
|
56,652,957
|
|
|
$
|
5,091,664
|
|
|
|
(51,836,696
|
)
|
|
$
|
9,907,925
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
18,160
|
|
|
|
-
|
|
|
|
18,160
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,656,477
|
)
|
|
|
(1,656,477
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - March 31, 2019
|
|
|
5,330,715
|
|
|
$
|
56,652,957
|
|
|
$
|
5,109,824
|
|
|
|
(53,493,173
|
)
|
|
$
|
8,269,608
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended March 31, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - September 30, 2018
|
|
|
5,330,715
|
|
|
$
|
56,652,957
|
|
|
$
|
5,064,625
|
|
|
|
(50,430,992
|
)
|
|
$
|
11,286,590
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
45,199
|
|
|
|
-
|
|
|
|
45,199
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(3,062,181
|
)
|
|
|
(3,062,181
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - March 31, 2019
|
|
|
5,330,715
|
|
|
$
|
56,652,957
|
|
|
$
|
5,109,824
|
|
|
|
(53,493,173
|
)
|
|
$
|
8,269,608
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
Total
|
|
|
|
|
|
|
Common
|
|
|
Share-Based
|
|
|
Accumulated
|
|
|
Shareholders'
|
|
|
|
Shares
|
|
|
Shares
|
|
|
Compensation
|
|
|
Deficit
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - December 31, 2017
|
|
|
1,502,870
|
|
|
$
|
48,351,701
|
|
|
$
|
4,460,106
|
|
|
|
(46,792,789
|
)
|
|
$
|
6,019,018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
73,462
|
|
|
|
-
|
|
|
|
73,462
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,352,527
|
)
|
|
|
(1,352,527
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - March 31,2018
|
|
|
1,502,870
|
|
|
$
|
48,351,701
|
|
|
$
|
4,533,568
|
|
|
|
(48,145,316
|
)
|
|
$
|
4,739,953
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended March 31, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - September 30, 2017
|
|
|
1,502,870
|
|
|
$
|
48,351,701
|
|
|
$
|
4,439,400
|
|
|
|
(45,392,043
|
)
|
|
$
|
7,399,058
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation
|
|
|
-
|
|
|
|
-
|
|
|
|
94,168
|
|
|
|
-
|
|
|
|
94,168
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,753,273
|
)
|
|
|
(2,753,273
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - March 31, 2018
|
|
|
1,502,870
|
|
|
$
|
48,351,701
|
|
|
$
|
4,533,568
|
|
|
|
(48,145,316
|
)
|
|
$
|
4,739,953
|
|
The accompanying notes are an integral
part of these condensed interim consolidated financial statements.
Stellar Biotechnologies, Inc.
|
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
Stellar Biotechnologies, Inc.
(the Company) is organized under the laws of British Columbia, Canada. The Company’s business is the aquaculture, research
and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). The Company markets and distributes its
KLH products to biotechnology and pharmaceutical companies, academic institutions, and clinical research organizations primarily
in Europe, Asia, and the United States. The Company’s common shares have been listed for trading on The Nasdaq Capital Market
in the United States under the symbol “SBOT” since November 5, 2015.
In April 2010, the Company changed
its name from CAG Capital, Inc. to Stellar Biotechnologies, Inc. and completed a reverse merger transaction with Stellar Biotechnologies,
Inc., a California corporation, which was founded in September 1999, and remains the Company’s wholly-owned subsidiary and
principal operating entity. In January 2017, the California subsidiary and the Company established a wholly-owned Mexican subsidiary
under the name BioEstelar, S.A. de C.V. in Ensenada, Baja California to perform aquaculture research and development activities
in Mexico. On March 29, 2019, the Company entered into an agreement to sell BioEstelar rather than pursue a more costly wind-down
of the subsidiary. The Company’s executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA,
and its registered and records office is 1500 Royal Centre, 1055 West Georgia Street, Vancouver, BC, V6E 4N7, Canada.
On March 7, 2019, the Company
entered into a Share Exchange Agreement (the Exchange Agreement) with Edesa Biotech Inc., a privately-held Canadian company focused
on the development of innovative therapeutics for dermatological and gastrointestinal indications (Edesa), and its shareholders.
Upon the terms and subject to the satisfaction of the conditions described in the Exchange Agreement, including approval of the
transaction by Stellar’s shareholders, Stellar will acquire the entire issued share capital of Edesa in exchange for newly-issued
Stellar common shares, with Edesa becoming a wholly-owned subsidiary of Stellar (the Exchange). Following the closing of the Exchange,
current Stellar shareholders are expected to own approximately 10%, and the current shareholders and option holders of Edesa are
expected to own approximately 90%, of the combined company on a fully-diluted basis, subject to a 2% upward or downward adjustment
based upon the amount of Stellar's working capital balance on the day before closing.
Liquidity
Company operations have historically
been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue and product sales.
For the six months ended March 31, 2019 and 2018, the Company reported net losses of $3.1 million and $2.8 million, respectively.
As of March 31, 2019, the Company had an accumulated deficit of $53.49 million and working capital of $7.26 million. The Company
expects to incur additional losses as it operates its business and pursues additional growth opportunities.
The Company plans to finance
company operations over the course of the next twelve months with cash and investments on hand and product sales. Management has
flexibility to adjust planned expenditures based on a number of factors including the size and timing of capital expenditures,
staffing levels, inventory levels, and the status of customer clinical trials. In light of the proposed share exchange agreement
with a third party, management has taken steps to conserve working capital, while maintaining the Company’s core competencies,
technology and associated activities. To help fund its operations and meet its obligations, the Company may also seek additional
financing through debt and/or equity financings in the future as and when it considers appropriate, subject to market conditions
and the availability of favorable terms.
The accompanying unaudited condensed
interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the
United States (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q. They do not include all information
and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with
U.S. GAAP for complete financial statements. These condensed interim consolidated financial statements should be read in conjunction
with the consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the
fiscal year ended September 30, 2018.
The accompanying condensed interim
consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, Stellar Biotechnologies,
Inc., a California corporation in the U.S. and, prior to March 29, 2019, BioEstelar, S.A. de C.V. a Baja California corporation
in Mexico. All significant intercompany balances and transactions have been eliminated in consolidation. All adjustments (consisting
of normal recurring adjustments and accruals) considered necessary for a fair presentation of the results of operations for the
period presented have been included in the interim period. Operating results for the six months ended March 31, 2019 are not necessarily
indicative of the results that may be expected for other interim periods or the fiscal year ending September 30, 2019. The condensed
interim consolidated financial data at September 30, 2018 is derived from audited financial statements included in the Company’s
Annual Report on Form 10-K for the fiscal year ended September 30, 2018, as filed on November 30, 2018 with the SEC.
The preparation of financial
statements in conformity with U.S. GAAP for interim financial information requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates.
Stellar Biotechnologies, Inc.
|
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
Functional Currency
The condensed interim consolidated
financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is the Company’s functional
currency.
Adoption of Recent Accounting
Pronouncements
On October 1, 2018, the Company
adopted Accounting Standards Codification (ASC) 606
Revenue Recognition – Revenue from Contracts with Customers
using
the modified retrospective method applied to those contracts which were not completed as of this date. Results for reporting periods
beginning after October 1, 2018 are presented under ASC Topic 606, while prior period amounts are not adjusted and continue to
be reported in accordance with the historical accounting under ASC Topic 605. There was no impact to the historical condensed interim
consolidated financial statements resulting from the Company’s adoption of ASC Topic 606.
Revenues and accounts receivable
are recognized when the promised goods or services are transferred to customers, in an amount that reflects the consideration to
which the Company expects to be entitled to in exchange for those goods or services. The Company’s revenue consists of sales
of its KLH products, which are recognized upon shipment when the customer obtains control of the product and the Company has no
further performance obligations. Deferred revenue is recorded when a customer pays consideration before they obtain control of
the product. The Company’s product sales by geographic area are presented in Note 9.
Short-term investments consisted
of U.S. Treasury Bills at March 31, 2019 and September 30, 2018. U.S. Treasury Bills are carried at amortized cost which approximates
fair value and are classified as held-to-maturity investments.
Raw materials include inventory
of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing
and testing, and allocated manufacturing overhead for inventory in process at the end of the period. Finished goods include products
that are complete and available for sale. At March 31, 2019 and September 30, 2018, the Company recorded work in process and finished
goods inventory only for those products with recent sales levels to evaluate net realizable value.
Inventory consisted of the following:
|
|
March 31,
|
|
|
September 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Raw materials
|
|
$
|
51,002
|
|
|
$
|
46,670
|
|
Work in process
|
|
|
149,789
|
|
|
|
83,297
|
|
Finished goods
|
|
|
43,181
|
|
|
|
94,300
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
243,972
|
|
|
$
|
224,267
|
|
|
5.
|
Property, Plant and Equipment,
net
|
Property, plant and equipment,
net consisted of the following:
|
|
March 31,
|
|
|
September 30,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
Aquaculture system
|
|
$
|
126,257
|
|
|
$
|
126,257
|
|
Laboratory facilities
|
|
|
62,033
|
|
|
|
62,033
|
|
Computer and office equipment
|
|
|
125,859
|
|
|
|
125,859
|
|
Manufacturing and laboratory equipment
|
|
|
990,492
|
|
|
|
1,042,993
|
|
Vehicles
|
|
|
49,347
|
|
|
|
77,994
|
|
Leasehold improvements
|
|
|
347,360
|
|
|
|
347,360
|
|
|
|
|
1,701,348
|
|
|
|
1,782,496
|
|
Less: accumulated depreciation
|
|
|
(1,179,976
|
)
|
|
|
(1,146,566
|
)
|
|
|
|
|
|
|
|
|
|
Depreciable assets, net
|
|
|
521,372
|
|
|
|
635,930
|
|
Construction in progress
|
|
|
475,373
|
|
|
|
426,265
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
996,745
|
|
|
$
|
1,062,195
|
|
Depreciation and amortization
expense amounted to approximately $80,000 and $96,000 for the six months ended March 31, 2019 and 2018, respectively.
Stellar Biotechnologies, Inc.
|
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
Operating leases
The Company leases buildings
and facilities used in its operations under two sublease agreements. In June 2015, the Company exercised its option to extend these
sublease agreements for an additional five-year term beginning in October and November 2015. The Company negotiated an option to
extend the leases for two additional five-year terms.
The Company leases facilities
used for executive offices and laboratories and pays a portion of the common area maintenance. In July 2018, the Company extended
this lease for a two-year term, with options to renew for three successive two-year terms.
The Company leased undeveloped
land in Baja California, Mexico to assess the potential development of an additional aquaculture locale and expansion of production.
In February 2018, the lease was transferred to its subsidiary BioEstelar and the Company has no further obligation under the lease
after the sale of its subsidiary on March 29, 2019.
Aggregate future minimum lease
payments at March 31, 2019 are as follows:
Year Ending September 30, 2019
|
|
|
92,000
|
|
Year Ending September 30, 2020
|
|
|
167,000
|
|
Year Ending September 30, 2021
|
|
|
6,000
|
|
|
|
|
|
|
|
|
$
|
265,000
|
|
Rent expense on these lease
agreements amounted to approximately $106,000 and $120,000 for the six months ended March 31, 2019 and 2018, respectively.
Purchase obligations
The Company has commitments
totaling approximately $10,000 at March 31, 2019 under signed agreements for leasehold improvements and equipment.
Supply agreements
The Company has commitments
under supply agreements with customers for fixed prices per gram of KLH in connection with clinical trials on a non-exclusive basis
except within that customer’s field of use. The expiration dates of these supply agreements range from October 2019 to February
2022, and are generally renewable upon written request of the customer.
Joint venture agreement
In May 2016, the Company entered
into a joint venture agreement with another party for the formation of a joint venture company to manufacture and sell conjugated
therapeutic vaccines. The joint venture is organized as a French simplified corporation. The Company holds a 30% equity interest
in the joint venture in exchange for an initial capital contribution of €120,000. One-half of the initial contribution, approximately
$67,000, was paid during the year ended September 30, 2016 with the balance due upon the occurrence of certain defined future events.
Pursuant to the joint venture agreement, on December 31, 2018, the Company notified the other party that it no longer wished to
pursue the project and the parties subsequently agreed to proceed with actions to dissolve and liquidate the joint venture company
by mutual consent. Impairment loss of approximately $30,000 is included in general and administrative expenses in the accompanying
condensed interim consolidated statements of operations for the six months ended March 31, 2019.
Retirement savings plan 401(k)
contributions
The Company sponsors a 401(k)
retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3% of eligible employee wages.
Contributions to the 401(k) plan were approximately $27,000 and $38,000 for the six months ended March 31, 2019 and 2018, respectively.
Related party commitments
On August 14, 2002, through
its California subsidiary, the Company entered into a patent royalty agreement with a director and officer of the Company, whereby
he would receive royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5% of gross receipts
from products using this invention in excess of $500,000 annually. The Company’s current operations utilize this invention.
There was no royalty expense incurred during the six months ended March 31, 2019 and 2018.
Reverse Share Split
On May 4, 2018, the Company
effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-7. As a result of the reverse
split, every seven shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding
common share, without par value, after fractional rounding. The number of warrants and options were proportionately adjusted by
the split ratio and the exercise prices correspondingly increased by the same split ratio. All shares and exercise prices are presented
on a post-split basis in these condensed interim consolidated financial statements.
Stellar Biotechnologies, Inc.
|
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
Black-Scholes option valuation
model
The Company uses the Black-Scholes
option valuation model to determine the fair value of share-based compensation for placement agent warrants and share options granted.
Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company
has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially
affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the
fair value of the Company’s warrants and share options.
Warrants
A summary of the Company’s warrants activity
is as follows:
|
|
Number of
Warrants
|
|
|
Weighted
Average
Exercise Price
|
|
|
|
|
|
|
|
|
Balance - September 30, 2017
|
|
|
180,805
|
|
|
$
|
31.50
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
5,665,528
|
|
|
|
2.68
|
|
Granted pre-funded warrants
|
|
|
687,076
|
|
|
|
.01
|
|
Exercised
|
|
|
(1,752,373
|
)
|
|
|
2.65
|
|
Exercised pre-funded warrants
|
|
|
(687,076
|
)
|
|
|
.01
|
|
|
|
|
|
|
|
|
|
|
Balance - September 30, 2018
|
|
|
4,093,960
|
|
|
$
|
3.96
|
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
(2,044,152
|
)
|
|
|
2.65
|
|
|
|
|
|
|
|
|
|
|
Balance - March 31, 2019
|
|
|
2,049,808
|
|
|
$
|
5.27
|
|
The weighted average contractual
life remaining on the outstanding warrants at March 31, 2019 is 48 months.
The following table summarizes information about
the warrants outstanding at March 31, 2019:
Exercise Price
|
|
|
Number of
Warrants
|
|
|
Expiry Date
|
|
|
|
|
|
|
|
$
|
31.50
|
|
|
|
180,805
|
|
|
January 2022
|
|
2.65
|
|
|
|
1,645,175
|
|
|
May 2023
|
|
3.31
|
|
|
|
223,828
|
|
|
May 2023
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,049,808
|
|
|
|
Share Options
The Company adopted an incentive
compensation plan in 2017 (the Incentive Plan), which amended and restated the 2013 fixed share option plan and is administered
by the Board of Directors. Options, restricted shares and restricted share units are eligible for grants under the Incentive Plan.
The number of shares available for issuance under the Incentive Plan is 228,143, including shares available for the exercise of
outstanding options under the 2013 fixed share option plan. No restricted shares or restricted share units have been granted as
of March 31, 2019.
The exercise price of an option
is set at the closing price of the Company’s common shares on the date of grant. Share options granted to directors, officers,
employees and certain individual consultants for past service are subject to the following vesting schedule: (a) one-third shall
vest immediately, (b) one-third shall vest at 12 months from the date of grant and (c) one-third shall vest at 18 months from the
date of grant.
Share options granted to directors,
officers, employees and certain individual consultants for future service are subject to the following vesting schedule: (x) one-third
shall vest at 12 months from the date of grant, (y) one-third shall vest at 24 months from the date of grant and (z) one-third
shall vest at 36 months from the date of grant.
Share options granted to certain
individual investor relations consultants are subject to the following vesting schedule: (aa) 25% shall vest at 3 months from the
date of grant, (bb) 25% shall vest at 6 months from the date of grant, (cc) 25% shall vest at 12 months from the date of grant
and (dd) 25% shall vest at 15 months from the date of grant.
Stellar Biotechnologies, Inc.
|
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
Options have been granted under
the Incentive Plan allowing the holders to purchase common shares of the Company as follows:
|
|
Number of
Options
|
|
|
Weighted
Average
Exercise Price
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance – September 30, 2017
|
|
|
58,711
|
|
|
$
|
40.18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
29,426
|
|
|
|
5.88
|
|
|
|
Expired
|
|
|
(2,266
|
)
|
|
|
84.87
|
|
|
|
Expired
|
|
|
(15,373
|
)
|
|
|
42.07
|
|
|
CDN $
|
|
|
|
|
|
|
|
|
|
|
|
Balance – September 30, 2018
|
|
|
70,498
|
|
|
$
|
25.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
2,142
|
|
|
|
1.25
|
|
|
|
Expired
|
|
|
(7,927
|
)
|
|
|
30.65
|
|
|
|
Expired
|
|
|
(7,786
|
)
|
|
|
56.73
|
|
|
CDN $
|
|
|
|
|
|
|
|
|
|
|
|
Balance – March 31, 2019
|
|
|
56,927
|
|
|
$
|
20.97
|
|
|
|
The weighted average contractual
life remaining on the outstanding options is 45 months.
The following table summarizes
information about the options under the Incentive Plan outstanding and exercisable at March 31, 2019:
Number of
Options
|
|
|
Exercisable at
March 31, 2019
|
|
|
Range of exercise prices
|
|
Expiry Dates
|
|
12,479
|
|
|
|
12,479
|
|
|
CDN$15.00 - 35.00
|
|
Apr 2019-Dec 2019
|
|
35,903
|
|
|
|
26,213
|
|
|
$1.00 - 20.00
|
|
Sep 2023-Mar 2026
|
|
2,214
|
|
|
|
2,214
|
|
|
CDN$40.00 - 70.00
|
|
May 2020-Jun 2022
|
|
1,901
|
|
|
|
1,901
|
|
|
$50.00 - 60.00
|
|
Dec 2022
|
|
1,644
|
|
|
|
1,644
|
|
|
CDN$105.00 - 110.00
|
|
Nov 2021
|
|
2,786
|
|
|
|
2,786
|
|
|
$120.00 - 130.00
|
|
Nov 2020
|
|
56,927
|
|
|
|
47,237
|
|
|
|
|
|
The estimated fair value of
the share options granted during the six months ended March 31, 2019 was determined using a Black-Scholes option valuation model
with the following weighted average assumptions:
|
|
Six Months Ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
Risk free interest rate
|
|
|
1.67
|
%
|
|
|
2.13
|
%
|
Expected life (years)
|
|
|
7.00
|
|
|
|
7.00
|
|
Expected share price volatility
|
|
|
153
|
%
|
|
|
155
|
%
|
Expected dividend yield
|
|
|
0
|
%
|
|
|
0
|
%
|
The weighted average fair value
of share options granted during the six months ended March 31, 2019 and 2018 was $1.20 and $5.67 respectively.
As of March 31, 2019, the Company
had approximately $23,000 of unrecognized share-based compensation expense, which is expected to be recognized over a period of
22 months.
|
8.
|
Fair Value of Financial
Instruments
|
The Company uses the fair value
measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting
pronouncements either permit or require fair value measurements.
Fair value of a financial instrument
is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts payable, accrued
liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Short-term investments
in U.S. Treasury Bills are recorded at amortized cost, which approximates fair value.
The Company follows the fair
value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when
measuring fair value. There are three levels of inputs that may be used to measure fair value:
|
Level 1:
|
Quoted prices in active markets for identical or similar assets and liabilities.
|
|
Level 2:
|
Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.
|
|
Level 3:
|
Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
|
Stellar Biotechnologies, Inc.
|
Notes to Condensed Interim Consolidated Financial Statements (Unaudited)
|
The Company reports its short-term
investments in U.S. Treasury Bills at fair value using Level 1 inputs in the fair value hierarchy.
The following table summarizes
fair values for those assets and liabilities with fair value measured on a recurring basis.
|
|
Fair Value Measurements Using
|
|
|
|
|
|
Quoted Prices in
Active Markets
for Identical
Instruments
(Level 1)
|
|
Significant
Other
Observable
Inputs
(Level 2)
|
|
|
Significant
Unobservable
Inputs
(Level 3)
|
|
|
Total Fair Value
|
|
September 30, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term investments in U.S. Treasury Bills
|
|
$6,078,031
|
|
$
|
-
|
|
|
$
|
-
|
|
|
$
|
6,078,031
|
|
There were no short-term investments
outstanding at March 31, 2019.
|
9.
|
Concentrations of Credit
Risk
|
Credit risk is the risk of an
unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments
that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, U.S Treasury
Bills, and accounts receivable. The Company estimates its maximum credit risk at the amount recorded on the balance sheet.
Management’s assessment
of the Company’s credit risk for cash and cash equivalents is low as they are held in major financial institutions believed
to be credit worthy or U.S. Treasury Bills with maturities of 90 days or less. The Company limits its exposure to credit loss for
short-term investments by holding U.S. Treasury Bills with maturities of 1 year or less. Based on credit monitoring and history,
the Company considers the risk of credit losses due to customer non-performance on accounts receivable to be low.
The Company had the following
concentrations of revenues by customers, each of which accounted for more than 10% of revenues in the applicable period:
|
|
Six Months Ended
|
|
|
March 31,
|
|
March 31,
|
|
|
2019
|
|
2018
|
|
|
|
|
|
Product sales
|
|
80% from
1 customer
|
|
72% from
2 customers
|
The Company had the following concentrations of revenues by
geographic areas:
|
|
Six Months Ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
North America
|
|
|
88
|
%
|
|
|
81
|
%
|
Europe
|
|
|
12
|
%
|
|
|
19
|
%
|
The Company had the following
concentrations of accounts receivable from its customers, each of which accounted for more than 10% in the applicable period:
|
|
March 31,
|
|
September 30,
|
|
|
2019
|
|
2018
|
|
|
|
|
|
Accounts receivable
|
|
88% from
2 customers
|
|
87% from
2 customers
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
|
The following management’s discussion
and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed interim
consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q as of March
31, 2019 and our audited consolidated financial statements for the year ended September 30, 2018 included in our Annual Report
on Form 10-K, filed with the Securities and Exchange Commission on November 30, 2018.
This Quarterly Report on Form 10-Q contains
certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities
Act) and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act) and, as such, may involve known and
unknown risks, uncertainties and assumptions. Forward-looking statements are based upon our current expectations, speak only as
of the date hereof, are subject to change and include statements concerning our financial performance, including expectations to
incur additional losses and plans to fund the Company. Forward-looking statements are those that predict or describe future events
or trends and that do not relate solely to historical matters. You can generally identify forward-looking statements as those statements
containing the words “anticipate,” “believe,” “plan,” “estimate,” “expect,”
“intend,” “may,” “will,” “would,” “could,” “should,” “might,”
“potential,” “continue” or other similar expressions. You should not rely on our forward-looking statements
as they are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate
because the matters they describe are subject to assumptions, known and unknown risks, uncertainties and other unpredictable factors,
many of which are beyond our control. Our actual results could differ materially and adversely from those expressed in any forward-looking
statements as a result of various factors, including the risks described in our Annual Report on Form 10-K for the year ended September
30, 2018 and other reports we file with the Securities and Exchange Commission. Risks and uncertainties include, among others,
the possibility that we may be unable to obtain shareholder approval required for the issuance of shares in the proposed Exchange,
the expected timing and likelihood of completion of the proposed Exchange, the possibility that our working capital decreases prior
to the Exchange, and therefore, that our shareholders are subject to decreased ownership in the combined company, the inability
to successfully integrate the businesses or the risk that such integration may be more difficult, time-consuming or costly than
expected, the occurrence of any event, change or other circumstances that could give rise to the termination of the share exchange
agreement, the inability of the parties to meet expectations regarding the accounting and tax treatments of the proposed Exchange,
the potential for the proposed Exchange to involve unexpected costs, the risk that the parties may not be able to satisfy the conditions
to the proposed Exchange in a timely manner or at all, risks related to disruption of management time from ongoing business operations
due to the proposed Exchange, the risk that the expected benefits of the proposed Exchange are not realized, the risk that any
announcements relating to the proposed Exchange could have adverse effects on the market price of our common shares, the availability
of funds and resources to pursue our research and development projects, the successful and timely completion of preclinical or
clinical studies by third parties in which our products are utilized, our ability to meet the goals of our strategic partnerships,
the degree of market acceptance for our products or for other companies’ products in which our products are components, our
ability to take advantage of business opportunities in the pharmaceutical industry, changes in our strategy or development plans,
our ability to protect our intellectual property, uncertainties related to governmental regulations and regulatory processes, the
volatility of our common share price, the effect of competition, the effect of technological changes, reliance on key personnel,
our ability to successfully estimate the impact of certain accounting and tax matters, and general changes in economic or business
conditions. Except as required by law, we undertake no obligation to update forward-looking statements.
The discussion and analysis of our financial
condition and results of operations are based on our unaudited condensed interim consolidated financial statements as of March
31, 2019 and September 30, 2018, and for the six months ended March 31, 2019 and 2018 included in Part I, Item 1 of this Quarterly
Report on Form 10-Q, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of
these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities
and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues
and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described
in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable
under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or
conditions.
Overview
We are a biotechnology company engaged
in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating
protein with an extensive history of safe and effective use in immunological applications.
Immunotherapies (also known as therapeutic
vaccines) are an emerging class of treatments that involve using the body’s own immune system to target and treat disease.
Today, multiple companies and institutions are developing drugs that combine disease-targeting agents with KLH. These disease-targeting
agents do not evoke a robust immune response by themselves and thus require a carrier molecule like KLH.
The versatility of the KLH molecule and
its use in multiple drug development pipelines provide numerous commercial opportunities for us. The successful commercialization
of one or more drug development pipelines, especially in a major indication, could have a significant impact on the industry’s
ability to produce sufficient quantities of KLH. The protein is derived only from the Giant Keyhole Limpet, a scarce ocean mollusk
that is native to a limited stretch of Pacific Ocean coastline. Due in part to the inherent limitations of utilizing wild sources
of KLH, we believe that aquaculture production methods and technologies will be required to provide scalable, fully traceable supplies
of KLH.
We market our products under the brand
Stellar KLH, including clinical grade KLH produced using Current Good Manufacturing Practices (GMP). Our customers and partners
have included multinational biotechnology and pharmaceutical companies, academic institutions, clinical research organizations
and research centers. We have multiple agreements to license and supply Stellar KLH and other technology in exchange for fees,
revenues or royalties. Our customers manage and fund all product development and regulatory submissions for their respective drug
products that utilize our KLH protein. By the time our customers are ready to file marketing applications referencing our
products, we will need to upgrade and scale our manufacturing operations to produce KLH suitable for commercial drugs. This will
involve, in part, transferring our manufacturing method to a new Stellar-operated location or to a contract manufacturing organization
or partner. The timing of such decision will be based on customer demand for Stellar KLH, among other considerations.
Recent Developments
Share Exchange Agreement
On March 7, 2019, we entered into a Share
Exchange Agreement (the Exchange Agreement) with Edesa Biotech Inc., a privately-held Canadian company focused on the development
of innovative therapeutics for dermatological and gastrointestinal indications with clear unmet medical needs (Edesa), and the
shareholders of Edesa. Upon the terms and subject to the satisfaction of the conditions described in the Exchange Agreement, including
approval of the transaction by Stellar’s shareholders, Stellar will acquire the entire issued share capital of Edesa in exchange
for newly-issued Stellar common shares, with Edesa becoming a wholly-owned subsidiary of Stellar (the Exchange). Following the
closing of the Exchange, current Stellar shareholders are expected to own approximately 10%, and the current shareholders and option
holders of Edesa are expected to own approximately 90%, of the combined company on a fully-diluted basis, subject to a 2% upward
or downward adjustment based upon the amount of Stellar's working capital balance on the day before closing. Following closing
of the Exchange, Stellar will change its name to "Edesa Biotech Inc." Considering the focus of the combined company,
we intend to develop a new strategic plan for our current operations following closing of the Exchange.
The Exchange Agreement contains customary
representations, warranties and covenants made by Stellar and Edesa, including covenants relating to Stellar’s and Edesa’s
conduct of their respective businesses between the date of signing the Exchange Agreement and the closing and customary no-solicitation
and standstill provisions. Edesa will seek approval from Nasdaq for the combined entity’s continuation of Stellar’s
current listing on the Nasdaq Capital Market.
Mexico Subsidiary
On March 29, 2019, Stellar Biotechnologies,
Inc. entered into an agreement to sell BioEstelar, S.A. de C.V., a wholly owned subsidiary based in Ensenada, Baja California,
Mexico, for a nominal consideration rather than pursue a more costly wind-down of the subsidiary. The loss on disposition of subsidiary
of $0.02 million is included in general and administrative expenses in the accompanying condensed interim consolidated financial
statements. Since 2017, BioEstelar has managed early-stage aquaculture research and development projects and a site suitability
study in Mexico for Stellar. In connection with the sale, BioEstelar intends to cancel its current lease agreements for undeveloped
land in Baja California and office space in Ensenada. We disposed of approximately $0.03 million leasehold improvements which is
included in research and development expenses in the accompanying condensed interim consolidated financial statements.
Neostell Joint Venture
In May 2016, we entered into a joint venture
agreement with Neovacs S.A, a Paris-based biotechnology company, for the formation of a joint venture company to manufacture and
sell conjugated therapeutic vaccines. In July 2016, Neostell S.A.S., a French simplified stock corporation (Neostell), was
formed to carry out the business of the joint venture. Neostell is expected to produce Neovacs’ product candidates
that utilize Stellar KLH as a carrier molecule and may also manufacture and sell other KLH-based immunotherapy products for third-party
customers. We hold a 30% equity interest in the joint venture in exchange for an initial capital contribution of €120,000.
One-half of the initial contribution, approximately $67,000, was paid in June 2016 with the balance due upon the occurrence of
certain defined future events. Pursuant to the joint venture agreement, on December 31, 2018, we notified the other party that
we no longer wished to pursue the project and the parties subsequently agreed to proceed with actions to dissolve and liquidate
the joint venture company by mutual consent.
Significant Accounting Policies
and Estimates
For a discussion
of our significant accounting policies and estimates, refer to Item 7, “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2018, as
filed with the Securities and Exchange Commission (SEC) on November 30, 2018. There are no material changes in our significant
accounting policies and estimates from the disclosure provided in our Annual Report on Form 10-K for the fiscal year ended September
30, 2018 except that the Company adopted Accounting Standards Codification (ASC) 606
Revenue Recognition – Revenue
from Contracts with Customers
on October 1, 2018, as discussed in Note 2 to this quarterly report.
Results of Operations
Comparison of the Six Months Ended March 31, 2019 and 2018
Our total revenues increased by $0.09 million
to $0.17 million for the six months ended March 31, 2019 compared to $0.08 million for the same period last year primarily due
to increased sales of higher value, clinical-grade KLH products. Product sales volumes are subject to variability associated with
the rate of development and progression of clinical studies of third-party products that utilize Stellar KLH.
Our total operating expenses increased
by $0.44 million to $3.26 million for the six months ended March 31, 2019 compared to $2.82 million for the same period last year:
|
·
|
Our cost of sales increased by $0.02 million to $0.09 million for the six months ended March 31, 2019 compared to $0.07 million for the same period last year primarily due to increased product sales.
|
|
·
|
Our cost of aquaculture decreased by $0.06 million to $0.11 million for the six months ended March 31, 2019 compared to $0.17 million for the same period last year primarily due to a decrease in contracted quality testing services, and decreased personnel expenses related to our intended shift to optimized habitats and cultivation systems, which require less staffing, and a postponement of equipment and materials purchases in response to the proposed share exchange agreement.
|
|
·
|
Our research and development expenses decreased by $0.27 million to $0.85 million for the six months ended March 31, 2019 compared to $1.12 million for the same period last year. The decrease was primarily due to a decrease in contracted research services and materials.
|
|
·
|
Our general and administrative expenses increased by $0.76 million to $2.21 million for the six months ended March 31, 2019 compared to $1.45 million for the same period last year
primarily due to increased legal and professional fees related to the proposed share exchange transaction and public company expenses
.
|
Our total other income (loss) increased
by $0.05 million to an overall gain of $0.03 million for the six months ended March 31, 2019 compared to an overall loss of $0.02
million for the same period last year primarily due to increased investment income, and reduced foreign exchange loss due to less
funds held in Canadian dollars and fluctuations in Canadian exchange rates.
Our net loss for the six months ended March
31, 2019 was $3.06 million, or $0.57 per basic share, compared to a net loss of $2.75 million, or $1.83 per basic share, for the
six months ended March 31, 2018.
Comparison of the Three Months Ended
March 31, 2019 and 2018
Our total revenues increased by $0.06 million
to $0.12 million for the three months ended March 31, 2019 compared to $0.06 million for the same period last year primarily due
to increased sales of higher value, clinical-grade KLH products. Product sales volumes are subject to variability associated with
the rate of development and progression of clinical studies of third-party products that utilize Stellar KLH.
Our total operating expenses increased
by $0.39 million to $1.80 million for the three months ended March 31, 2019 compared to $1.41 million for the same period last
year.
|
·
|
While product sales increased, our cost of sales remained relatively unchanged at $0.06 million for the three months ended March 31, 2019 compared to the same period last year primarily due to higher margins on clinical-grade KLH products.
|
|
·
|
Our cost of aquaculture decreased by $0.03 million to $0.04 million for the three months ended March 31, 2019 compared to $0.07 million for the same period last year primarily due to decreased personnel expenses related to our intended shift to optimized habitats and cultivation systems, which require less staffing, and a postponement of equipment and materials purchases in response to the proposed share exchange agreement.
|
|
·
|
Our research and development expenses decreased by $0.11 million to $0.38 million for the three months ended March 31, 2019 compared to $0.49 million for the same period last year primarily due to a decrease in contracted research services and materials and decreased personnel costs.
|
|
·
|
Our general and administrative expenses increased by $0.56 million to $1.33 million for the three months ended March 31, 2019 compared to $0.77 million for the same period last year
primarily due to increased legal and professional fees related to the proposed share exchange transaction
.
|
Our total other income (loss) increased
by $0.04 million to an overall gain of $0.03 million for the three months ended March 31, 2019 compared to an overall loss of $0.01
million for the same period last year primarily due to increased investment income, and foreign exchange gain due to fluctuations
in Canadian exchange rates.
Our net loss for the three months ended
March 31, 2019 was $1.66 million, or $0.31 per basic share, compared to a net loss of $1.35 million, or $0.90 per basic share,
for the three months ended March 31, 2018.
Capital Expenditures
Our capital expenditures, which primarily
consist of scientific, manufacturing, and aquaculture equipment, and facility leasehold improvements were $0.01 million and $0.21
million for the six months ended March 31, 2019 and 2018, respectively. The decrease was due primarily to a decrease in construction
in progress related to the completion of construction of renovated ocean-front space for aquaculture production and related activities
at our facility located at the Port of Hueneme.
Liquidity and Capital Resources
Our operations have historically been
funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue and product sales. For
the six months ended March 31, 2019 and 2018, the Company reported net losses of $3.06 million and $2.75 million, respectively.
We plan to finance company operations over the course of the next twelve months with cash and investments on hand and product
sales. Management has flexibility to adjust planned expenditures based on a number of factors including the size and timing of
capital expenditures, staffing levels, inventory levels, and the status of customer clinical trials. In light of the proposed
share exchange agreement with Edesa Biotech Inc, management has taken steps to conserve working capital, while maintaining our
core competencies, technology and associated activities. To help fund its operations and meet its obligations, the Company may
also seek additional financing through debt and/or equity financings.
On May 15, 2018, we completed a registered
public offering resulting in net proceeds of $4.64 million. On May 29, 2018, we closed an offering with certain holders of
our warrants, pursuant to a warrant exercise agreement, resulting in net proceeds of $2.49 million. During May and June 2018, other
warrant exercises resulted in net proceeds of $1.64 million.
At March 31, 2019, we had cash, cash equivalents
and short-term investments in U.S. Treasury Bills of $7.68 million, working capital of $7.26 million, shareholders’ equity
of $8.27 million and an accumulated deficit of $53.49 million.
Geographic Concentrations
We primarily market and distribute our
products directly to biotechnology and pharmaceutical companies, academic institutions, clinical research organizations and research
centers. Products are shipped to our customers using a common carrier chosen by the customer. The geographic markets of our customers
are principally North America, Europe and Asia. We had the following concentrations of revenues by geographic areas:
|
|
Six Months Ended
|
|
|
|
March 31,
|
|
|
March 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
|
|
|
|
|
|
|
|
North America
|
|
|
88
|
%
|
|
|
81
|
%
|
Europe
|
|
|
12
|
%
|
|
|
19
|
%
|
The geographic concentration of our product
sales revenue fluctuates quarter over quarter, sometimes significantly, depending on the volume of sales from our customers in
each of our principal geographic markets.
Research and Development
Our core business is developing and commercializing
Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. Our internal research has included, among
other activities, continual improvement of methods for the culture and growth of Giant Keyhole Limpet, innovations in aquaculture
systems and infrastructure, biophysical and biochemical characterization of the KLH molecule, analytical processes to enhance performance
of our products, KLH manufacturing process improvements, new KLH formulations, and early development of potential new KLH-based
immunotherapies.
Research and development costs, including
(i) materials, (ii) KLH designated for internal research use only and (iii) salaries of employees directly involved in research
and development efforts, are expensed as incurred. From time to time, we produce saleable KLH as a byproduct of our research and
development activities. The cost of this KLH is not assigned to inventory.
Our research and development costs were
$0.85 million and $1.12 million for the six months ended March 31, 2019 and 2018, respectively. The decrease from the comparable
period was primarily due to a decrease in contracted research services and materials.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.